Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer | Zendy

Matthew P. Deek | Zendy; Nikhil YegyaRaman | Zendy; Parima Daroui | Zendy; S. Balasubramanian | Zendy; Jyoti Malhotra | Zendy; Dirk F. Moore | Zendy; Malini Patel | Zendy; Shang-Jui Wang | Zendy; Joseph Aisner | Zendy; Salma K. Jabbour | Zendy

Open Access

Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer

Author(s) -

Matthew P. Deek,

Nikhil YegyaRaman,

Parima Daroui,

S. Balasubramanian,

Jyoti Malhotra,

Dirk F. Moore,

Malini Patel,

Shang-Jui Wang,

Joseph Aisner,

Salma K. Jabbour

Publication year - 2021

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-21-182

Subject(s) - ercc1 , medicine , hazard ratio , oncology , proportional hazards model , lung cancer , survival analysis , dna repair , gene , nucleotide excision repair , confidence interval , biology , biochemistry

Locally advanced non-small cell lung cancer (NSCLC) is typically treated with concurrent chemoradiation (CRT). Excision Repair Cross-Complementing 1 (ERCC1) is a protein involved in DNA damage repair. The objective of this study was to assess whether higher tumoral ERCC1 expression would associate with worse clinical outcomes in NSCLC treated with CRT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research